The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).
 
Sarina A. Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Hengrui Pharmaceutical (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Jiangsu Simcere Pharmaceutical Co. Ltd. (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); Novartis (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Purinomia (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Shasqi Inc. (Inst); Shasqi Inc. (Inst); Silverback Therapeutics (Inst); Synlogic (Inst); Taiho Oncology (Inst); Tallac Therapeutics, Inc. (Inst); Tesaro (Inst); Theradex (Inst); Theradex (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); Xencor (Inst); ZielBio (Inst)
 
Justin A Call
No Relationships to Disclose
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Jorge Bartolome
No Relationships to Disclose
 
Maria J. de Miguel
Honoraria - Janssen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi
 
Yangchun Du
Employment - Mural Oncology
Stock and Other Ownership Interests - Mural Oncology
 
Clifford DiLea
Employment - Mural Oncology
Stock and Other Ownership Interests - Mural Oncology
 
Sonali Panchabhai
Employment - Mural Oncology
Stock and Other Ownership Interests - Mural Oncology
 
Nehal J. Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)